Adaptation of international guidelines for metastatic colorectal cancer: An Asian consensus

Ann Lii Cheng; Jin Li; Ashok K. Vaid; Brigette Buig Yue Ma; Catherine Teh; Joong B. Ahn; Maximino Bello; Chaiyut Charoentum; Li Tzong Chen; Gilberto De Lima Lopes; Gwo F. Ho; Hwai L. Kong; Ka O. Lam; Tian S. Liu; Young S. Park; Virote Sriuranpong; Aru W. Sudoyo; Jaw Yuan Wang; Jun Zhang; Su Z. Zhang; Fortunato Ciardiello; Clause Henning Köhne; Michael Shaw; Tae Won Kim

doi:10.1016/j.clcc.2014.06.004

Adaptation of international guidelines for metastatic colorectal cancer: An Asian consensus

Ann Lii Cheng, Jin Li, Ashok K. Vaid, Brigette Buig Yue Ma, Catherine Teh, Joong B. Ahn, Maximino Bello, Chaiyut Charoentum, Li Tzong Chen, Gilberto De Lima Lopes, Gwo F. Ho, Hwai L. Kong, Ka O. Lam, Tian S. Liu, Young S. Park, Virote Sriuranpong, Aru W. Sudoyo, Jaw Yuan Wang, Jun Zhang, Su Z. ZhangFortunato Ciardiello, Clause Henning Köhne, Michael Shaw, Tae Won Kim

Department of Medical Education

Research output: Contribution to journal › Comment/debate

16 Citations (Scopus)

Abstract

Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). A multidisciplinary expert panel, consisting of 23 participants from 10 Asian and 2 European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice. Participants agreed that mCRC management in Asia largely follows international guidelines, but they proposed a number of recommendations based on regional 'real-world' experience. In general, participants agreed that 5-fluorouracil (5-FU) infusion regimens in doublets can be substituted with UFT (capecitabine, tegafur-uracil) and S1 (tegafur, 5-chloro-2,4-dihydroxypyridine and oxonic acid), and that the monoclonal antibodies cetuximab and panitumumab are recommended for KRAS wild type tumors. For KRAS mutant tumors, bevacizumab is the preferred biological therapy. FOLFOX (folinic acid, 5-FU, and oxaliplatin) is preferred for initial therapy in Asian patients. The management of mCRC is evolving, and it must be emphasized that the recommendations presented here reflect current treatment practices and thus might change as more data become available.

Original language	English
Pages (from-to)	145-155
Number of pages	11
Journal	Clinical Colorectal Cancer
Volume	13
Issue number	3
DOIs	https://doi.org/10.1016/j.clcc.2014.06.004
Publication status	Published - 1 Sept 2014

Keywords

Asia
Chemotherapy
Epidermal growth factor receptor (EGFR)-specific monoclonal antibody
KRAS
Targeted therapy

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.clcc.2014.06.004

Cite this

Cheng, A. L., Li, J., Vaid, A. K., Ma, B. B. Y., Teh, C., Ahn, J. B., Bello, M., Charoentum, C., Chen, L. T., De Lima Lopes, G., Ho, G. F., Kong, H. L., Lam, K. O., Liu, T. S., Park, Y. S., Sriuranpong, V., Sudoyo, A. W., Wang, J. Y., Zhang, J., ... Kim, T. W. (2014). Adaptation of international guidelines for metastatic colorectal cancer: An Asian consensus. Clinical Colorectal Cancer, 13(3), 145-155. https://doi.org/10.1016/j.clcc.2014.06.004

@article{c434d6a245254d758bf6351a620c29f3,

title = "Adaptation of international guidelines for metastatic colorectal cancer: An Asian consensus",

abstract = "Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). A multidisciplinary expert panel, consisting of 23 participants from 10 Asian and 2 European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice. Participants agreed that mCRC management in Asia largely follows international guidelines, but they proposed a number of recommendations based on regional 'real-world' experience. In general, participants agreed that 5-fluorouracil (5-FU) infusion regimens in doublets can be substituted with UFT (capecitabine, tegafur-uracil) and S1 (tegafur, 5-chloro-2,4-dihydroxypyridine and oxonic acid), and that the monoclonal antibodies cetuximab and panitumumab are recommended for KRAS wild type tumors. For KRAS mutant tumors, bevacizumab is the preferred biological therapy. FOLFOX (folinic acid, 5-FU, and oxaliplatin) is preferred for initial therapy in Asian patients. The management of mCRC is evolving, and it must be emphasized that the recommendations presented here reflect current treatment practices and thus might change as more data become available.",

keywords = "Asia, Chemotherapy, Epidermal growth factor receptor (EGFR)-specific monoclonal antibody, KRAS, Targeted therapy",

author = "Cheng, {Ann Lii} and Jin Li and Vaid, {Ashok K.} and Ma, {Brigette Buig Yue} and Catherine Teh and Ahn, {Joong B.} and Maximino Bello and Chaiyut Charoentum and Chen, {Li Tzong} and {De Lima Lopes}, Gilberto and Ho, {Gwo F.} and Kong, {Hwai L.} and Lam, {Ka O.} and Liu, {Tian S.} and Park, {Young S.} and Virote Sriuranpong and Sudoyo, {Aru W.} and Wang, {Jaw Yuan} and Jun Zhang and Zhang, {Su Z.} and Fortunato Ciardiello and K{\"o}hne, {Clause Henning} and Michael Shaw and Kim, {Tae Won}",

year = "2014",

month = sep,

day = "1",

doi = "10.1016/j.clcc.2014.06.004",

language = "English",

volume = "13",

pages = "145--155",

journal = "Clinical Colorectal Cancer",

issn = "1533-0028",

publisher = "Elsevier",

number = "3",

}

Cheng, AL, Li, J, Vaid, AK, Ma, BBY, Teh, C, Ahn, JB, Bello, M, Charoentum, C, Chen, LT, De Lima Lopes, G, Ho, GF, Kong, HL, Lam, KO, Liu, TS, Park, YS, Sriuranpong, V, Sudoyo, AW, Wang, JY, Zhang, J, Zhang, SZ, Ciardiello, F, Köhne, CH, Shaw, M & Kim, TW 2014, 'Adaptation of international guidelines for metastatic colorectal cancer: An Asian consensus', Clinical Colorectal Cancer, vol. 13, no. 3, pp. 145-155. https://doi.org/10.1016/j.clcc.2014.06.004

TY - JOUR

T1 - Adaptation of international guidelines for metastatic colorectal cancer

T2 - An Asian consensus

AU - Cheng, Ann Lii

AU - Li, Jin

AU - Vaid, Ashok K.

AU - Ma, Brigette Buig Yue

AU - Teh, Catherine

AU - Ahn, Joong B.

AU - Bello, Maximino

AU - Charoentum, Chaiyut

AU - Chen, Li Tzong

AU - De Lima Lopes, Gilberto

AU - Ho, Gwo F.

AU - Kong, Hwai L.

AU - Lam, Ka O.

AU - Liu, Tian S.

AU - Park, Young S.

AU - Sriuranpong, Virote

AU - Sudoyo, Aru W.

AU - Wang, Jaw Yuan

AU - Zhang, Jun

AU - Zhang, Su Z.

AU - Ciardiello, Fortunato

AU - Köhne, Clause Henning

AU - Shaw, Michael

AU - Kim, Tae Won

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). A multidisciplinary expert panel, consisting of 23 participants from 10 Asian and 2 European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice. Participants agreed that mCRC management in Asia largely follows international guidelines, but they proposed a number of recommendations based on regional 'real-world' experience. In general, participants agreed that 5-fluorouracil (5-FU) infusion regimens in doublets can be substituted with UFT (capecitabine, tegafur-uracil) and S1 (tegafur, 5-chloro-2,4-dihydroxypyridine and oxonic acid), and that the monoclonal antibodies cetuximab and panitumumab are recommended for KRAS wild type tumors. For KRAS mutant tumors, bevacizumab is the preferred biological therapy. FOLFOX (folinic acid, 5-FU, and oxaliplatin) is preferred for initial therapy in Asian patients. The management of mCRC is evolving, and it must be emphasized that the recommendations presented here reflect current treatment practices and thus might change as more data become available.

AB - Colorectal cancer (CRC) is among the most common cancers worldwide, but marked epidemiological differences exist between Asian and non-Asian populations. Hence, a consensus meeting was held in Hong Kong in December 2012 to develop Asia-specific guidelines for the management of metastatic CRC (mCRC). A multidisciplinary expert panel, consisting of 23 participants from 10 Asian and 2 European countries, discussed current guidelines for colon or rectal cancer and developed recommendations for adapting these guidelines to Asian clinical practice. Participants agreed that mCRC management in Asia largely follows international guidelines, but they proposed a number of recommendations based on regional 'real-world' experience. In general, participants agreed that 5-fluorouracil (5-FU) infusion regimens in doublets can be substituted with UFT (capecitabine, tegafur-uracil) and S1 (tegafur, 5-chloro-2,4-dihydroxypyridine and oxonic acid), and that the monoclonal antibodies cetuximab and panitumumab are recommended for KRAS wild type tumors. For KRAS mutant tumors, bevacizumab is the preferred biological therapy. FOLFOX (folinic acid, 5-FU, and oxaliplatin) is preferred for initial therapy in Asian patients. The management of mCRC is evolving, and it must be emphasized that the recommendations presented here reflect current treatment practices and thus might change as more data become available.

KW - Asia

KW - Chemotherapy

KW - Epidermal growth factor receptor (EGFR)-specific monoclonal antibody

KW - KRAS

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84908126534&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2014.06.004

DO - 10.1016/j.clcc.2014.06.004

M3 - Comment/debate

C2 - 25209093

AN - SCOPUS:84908126534

SN - 1533-0028

VL - 13

SP - 145

EP - 155

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

IS - 3

ER -

Adaptation of international guidelines for metastatic colorectal cancer: An Asian consensus

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this